PMID- 31696054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 9
DP  - 2019
TI  - Exosomes Derived From MicroRNA-148b-3p-Overexpressing Human Umbilical Cord 
      Mesenchymal Stem Cells Restrain Breast Cancer Progression.
PG  - 1076
LID - 10.3389/fonc.2019.01076 [doi]
LID - 1076
AB  - Exosomes derived from human umbilical cord mesenchymal stem cells (HUCMSCs) 
      expressing microRNAs (miRs) have been highlighted as important carriers for gene 
      or drug therapy. Hence, this study aimed to explore the role of exosomal 
      miR-148b-3p from HUCMSCs in breast cancer. Clinical samples subjected to RT-qPCR 
      detection revealed that miR-148b-3p was poorly expressed, while tripartite motif 
      59 (TRIM59) was highly expressed in breast cancer tissues. Online analyses 
      available at miRanda, TargetScan, and miRbase databases revealed that miR-148b-3p 
      could bind to TRIM59, while dual-luciferase reporter gene assay further verified 
      that TRIM59 was a target gene of miR-148b-3p. Next, miR-148b-3p mimic or 
      inhibitor and siRNA against TRIM59 were delivered into the breast cancer cells 
      (MDA-MB-231) to alter the expression of miR-148b-3p and TRIM59 so as to evaluate 
      their respective effects on breast cancer cellular processes. Evidence was 
      obtained demonstrating that miR-148b-3p inhibited cell proliferation, invasion, 
      and migration, but promoted cell apoptosis in breast cancer by down-regulating 
      TRIM59. Next, MDA-MB-231 cells were co-cultured with the exosomes derived from 
      HUCMSCs expressing miR-148b-3p. The results of co-culture experiments 
      demonstrated that HUCMSCs-derived exosomes carrying miR-148b-3p exerted 
      inhibitory effects on MDA-MB-231 progression in vitro. In vivo experimentation 
      further confirmed the anti-tumor effects of HUCMSCs-derived exosomes carrying 
      miR-148b-3p. Taken together, HUCMSC-derived exosomes carrying miR-148b-3p might 
      suppress breast cancer progression, which highlights the potential of exosomes 
      containing miR-148b-3p as a promising therapeutic approach for breast cancer 
      treatment.
CI  - Copyright (c) 2019 Yuan, Liu, Qu, Liu and Li.
FAU - Yuan, Lei
AU  - Yuan L
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Liu, Yuqiong
AU  - Liu Y
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Qu, Yunhui
AU  - Qu Y
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Liu, Lan
AU  - Liu L
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Li, Huixiang
AU  - Li H
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20191022
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC6817568
OTO - NOTNLM
OT  - TRIM59
OT  - breast cancer
OT  - exosomes
OT  - human umbilical cord mesenchymal stem cell
OT  - miR-148b-3p
EDAT- 2019/11/07 06:00
MHDA- 2019/11/07 06:01
PMCR- 2019/01/01
CRDT- 2019/11/08 06:00
PHST- 2019/03/14 00:00 [received]
PHST- 2019/09/30 00:00 [accepted]
PHST- 2019/11/08 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2019/11/07 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2019.01076 [doi]
PST - epublish
SO  - Front Oncol. 2019 Oct 22;9:1076. doi: 10.3389/fonc.2019.01076. eCollection 2019.